Skip to main content

Catalio Capital Management — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

132
Companies
$12.7B
Total invested
$93.1M
Avg. check
27
Industries
Health Care 16Biotechnology 15Therapeutics 9Medical 9Life Science 6Medical Device 4+21 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 132
Beacon Biosignals
April 2026

Beacon Biosignals is a neurotechnology company that brings precision neuroscience into clinical trials and treatments.

Artificial Intelligence (AI) · Boston$11.0M Series B
Pheast Therapeutics
April 2022

Pheast Therapeutics develops checkpoint therapies to harness the innate immune system.

Biotechnology · Palo Alto$76.0M Series A
Neumora Therapeutics
April 2024

Neumora Therapeutics operates as a clinical-stage biotechnology company.

Biotechnology · Watertown$2.6M Grant
Spiral Therapeutics
April 2026

Spiral Therapeutics is a clinical-stage pharmaceutical company delivering therapies for inner ear disorders.

Biotechnology · San Francisco$27.0M Series B
Satellite Bio
March 2022

Satellite Bio specializes in cell therapy, regenerative medicine, synthetic biology, cell biology, and tissue engineering.

Biopharma · Newton$82.5M Series A
Avava
March 2026

Avava is a Pioneer precision skin therapy to improve the quality of life for patients around the world.

Health Care · Waltham$19.6M Series D
Celsius Therapeutics
March 2022

Celsius Therapeutics is a biotechnology company that develops precision medicines for cancer and autoimmune disease patients.

Biotechnology · Cambridge$83.0M Series B
Affini-T Therapeutics
March 2022

Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.

Biotechnology · Watertown$175.0M Venture - Series Unknown
Clasp Therapeutics
March 2024

Clasp Therapeutics offers to reach of immuno-oncology with novel precision medicines that enable the immune system.

Biotechnology · Cambridge$150.0M Series A
Hyperfine
March 2026

Hyperfine makes MRI accessible to every patient regardless of income or resources.

Computer · Guilford$40.0M Post-IPO Debt
Imperative Care
March 2026

Imperative Care is singularly dedicated to finding meaningful answers to unsolved problems in stroke.

Health Care · Campbell$100.0M Convertible Note
Dianthus Therapeutics
March 2026

Dianthus Therapeutics is a biotech company developing new treatments for serious autoimmune diseases using a more targeted approach.

Biopharma · Waltham$719.0M Post-IPO Equity
DNA Script
February 2025

DNA Script is a disruptive DNA synthesis company harnessing biology to accelerate breakthroughs in life science and human health.

Biotechnology · Le Kremlin-bicêtre$4.7M Grant
COMPASS Pathways
February 2026

Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression.

Biotechnology · Altrincham$200.0M Post-IPO Equity
ProSomnus Sleep Technologies
February 2026

ProSomnus designs and manufactures intraoral devices designed to help dentists get patients into therapy with comfort.

Health Care · Pleasanton$38.0M Venture - Series Unknown
Perceive Pharma
February 2025

Perceive Pharma operates as a pharmaceutical company.

Life Science · San Francisco$15.0M Series A
NextPoint Therapeutics
February 2024

NextPoint Therapeutics is a clinical-stage biotechnology company that develops therapeutics to treat cancer patients.

Biotechnology · Cambridge$42.5M Series B
Somethings
February 2026

Somethings is a platform for wellness tailored to young people that links youngsters with qualified mentors.

Health Care · New York$19.2M Series A
Star Therapeutics
September 2025

Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.

Health Care · South San Francisco$125.0M Series D
Ensoma
September 2025

Ensomaa is a genomic medicine company that develops on one-time in vivo treatments for immuno-oncology and other therapeutic applications.

Biotechnology · Boston$53.0M Venture - Series Unknown
Character Biosciences
September 2025

Character Bio is a platform that merges genomics with clinical data and AI technology, focusing on patients affected by AMD.

Artificial Intelligence (AI) · Jersey City$17.0M Series B
Enveda Biosciences
September 2025

Enveda Biosciences is a biotechnology company that develops novel medications derived from plants.

Biotechnology · Boulder$150.0M Series D
OSPRI
August 2025

OSPRI is updating the infectious illness testing plan.

Biotechnology · Mckinney$30.0M Venture - Series Unknown
Amalgam Rx
August 2025

Amalgam Rx develops and distributes digital health products that support patients and healthcare providers in decision-making.

CRM · Wilmington$7.9M Venture - Series Unknown

Where Catalio Capital Management invests

Health Care16
Biotechnology15
Therapeutics9
Medical9
Life Science6
Medical Device4

About Catalio Capital Management's portfolio

How many companies has Catalio Capital Management invested in?

Catalio Capital Management has invested in 132 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Catalio Capital Management invest in?

Catalio Capital Management's top investment sectors include Health Care, Biotechnology, Therapeutics, Medical, Life Science. The firm invests across 27 different industry categories.

What is Catalio Capital Management's largest investment?

Among tracked funding rounds, Dianthus Therapeutics received $719.0M in a Post-IPO Equity round. Catalio Capital Management's total known invested capital is $12.7B.

What is the average investment size for Catalio Capital Management?

Catalio Capital Management's average investment size is $93.1M across its portfolio of 132 companies.

What are Catalio Capital Management's most recent investments?

Recent Catalio Capital Management portfolio additions include Beacon Biosignals, Pheast Therapeutics, Neumora Therapeutics, Spiral Therapeutics, Satellite Bio. These companies were founded in 2020 or later.

Reach the founders behind these 132 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →